Maślan sodu - drogowskazy terapeutyczne Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2024
Słowa kluczowe:
maślan sodu, krótkołańcuchowe kwasy tłuszczowe, zespół jelita nadwrażliwego
##plugins.themes.bootstrap3.article.main##
Abstrakt
Maślan sodu jest solą sodową kwasu masłowego, krótkołańcuchowego kwasu tłuszczowego, który ma m.in. silne działanie troficzne na nabłonek jelitowy. Wpływ suplementacji maślanem sodu budzi zainteresowanie wielu dziedzin medycyny: gastroenterologii, diabetologii czy onkologii. Najszerzej opisano korzystne działanie tej substancji w łagodzeniu objawów zespołu jelita nadwrażliwego, ale w literaturze opisywany jest również jej wpływ na gospodarkę węglowodanową czy leczenie nieswoistych chorób zapalnych jelit.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Panufnik, P., Banasiewicz, T., & Rydzewska, G. (2024). Maślan sodu - drogowskazy terapeutyczne . Medycyna Faktów , 17(1(62), 121-128. https://doi.org/10.24292/01.MF.0124.19
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Dąbek-Drobny A, Kaczmarczyk O, Woźniakiewicz M et al. Association between Fecal Short-Chain Fatty Acid Levels, Diet, and Body Mass Index in Patients with Inflammatory Bowel Disease. Biology (Basel). 2022; 11(1): 108.
2. Tsukahara T, Koyama H, Okada M et al. Stimulation of butyrate production by gluconic acid in batch culture of pig cecal digesta and identification of butyrateproducing bacteria. J Nutr. 2002; 132: 222934.
3. Kiani AK, Medori MC, Bonetti G et al. Modern vision of the Mediterranean diet. J Prev Med Hyg. 2022; 63(2 Suppl 3): E36-43.
4. Newsome R, Yang Y, Jobin C. Western diet influences on microbiome and carcinogenesis. Semin Immunol. 2023; 67: 101756.
5. García-Montero C, Fraile-Martínez O, Gómez-Lahoz AM et al. Nutritional Components in Western Diet Versus Mediterranean Diet at the Gut Microbiota-Immune System Interplay. Implications for Health and Disease. Nutrients. 2021; 13(2): 699.
6. Coppola S, Avagliano C, Calignano A et al. The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. Molecules. 2021; 26: 682.
7. Banasiewicz T. Badanie porównujące profil uwalniania się w jelicie aktualnie dostępnych na rynku polskim produktów zawierających maślan sodu. Med Fakt. 2017; 4(37).
8. Chapman MA, Grahn MF, Boyle MA et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994; 35(1): 73-6.
9. Tarnowski W, Borycka-Kiciak K, Kiciak A et al. Efekty leczenia kwasem masłowym w zespole jelita drażliwego – doniesienie wstępne. Gastroenterol Prakt. 2013; 1 : 43-8.
10. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012; 15(5): 474-9.
11. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol. 2013; 15(2): 204-49.
12. Pozuelo M, Panda S, Santiago A et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep. 2015; 5: 12693.
13. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013; 15(2): 204-9.
14. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34.
15. Parada Venegas D, De la Fuente MK, Landskron G et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019; 10: 277.
16. Deleu S, Machiels K, Raes J et al. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine. 2021; 66: 103293.
17. Facchin S, Vitulo N, Calgaro M et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020; 32(10): e13914.
18. Pietrzak A, Banasiuk M, Szczepanik M et al. Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial. Nutrients. 2022; 14(16): 3283.
19. Karłowicz K, Lewandowski K, Tulewicz-Marti E et al. P876 Efficacy and safety of microencapsulated butyrate add-on therapy in induction of remission in patients with mild-to-moderate Ulcerative Colitis – results from multi-center, double-blind, randomized, placebo-controlled clinical study. Journal of Crohn’s and Colitis. 2024; 18(1): i1618.
20. Krokowicz L, Stojcev Z, Kaczmarek BF et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis – a prospective randomized study. Int J Colorectal Dis. 2014; 29(3): 387-93.
21. Bajka BH, Clarke JM, Topping DL et al. Butyrylated starch increases large bowel butyrate levels and lowers colonic smooth muscle contractility in rats. Nut Res. 2010; 30: 427-34.
22. Hodgkinson K, El Abbar F, Dobranowski P et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. 2023; 42(2): 61-75.
23. Tseng CH, Wu CY. The gut microbiome in obesity. J Formos Med Assoc. 2019; 118(Suppl 1): S3-S9.
24. van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. Obes Rev. 2022; 23(10): e13498.
25. Zhou D, Chen YW, Zhao ZH et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018; 50(12): 1-12.
26. Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. Chem Biol Interact. 2016; 254: 124-34.
27. Park M, Kwon J, Shin HJ et al. Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patientderived organoids. Int J Oncol. 2020; 57(6): 1307-18.
28. Encarnação JC, Pires AS, Amaral RA et al. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J Nutr Biochem. 2018; 56: 183-92.
29. Xi Y, Jing Z, Wei W et al. Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network. BMC Cancer. 2021; 21(1): 127.
30. Pinto A, Fidalgo P, Cravo M et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double- blind, controlled trial. Dis Colon Rectum. 1999; 42(6): 788-95.
31. Harig JM, Soergel KH, Komorowski RA et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med. 1989; 320(1): 23-8.
32. Mortensen FV, Hessov I, Birke H et al. Microcirculatory and trophic effects of short chain fatty acids in the human rectum after Hartmann’s procedure. Br J Surg. 1991; 78(10): 1208-11.
33. Brown AJ, Goldsworthy SM, Barnes AA et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003; 278(13): 11312-9.
34. Nilsson NE, Kotarsky K, Owman C et al. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun. 2003; 303: 1047-52.
35. Tolhurst G, Heffron H, Lam YS et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012; 61(2): 364-71.
36. Yadav H, Lee JH, Lloyd J et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013; 288(35): 25088-97.
37. Nohr MK, Pedersen MH, Gille A et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology. 2013; 154(10): 3552-64.
38. Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. Chem Biol Interact. 2016; 254: 124-34.
39. Roshanravan N, Mahdavi R, Alizadeh E et al. Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucago-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. Horm Metab Res. 2017; 49(11): 886-91.
40. Coppola S, Nocerino R, Paparo L et al. Butyrate against paediatric obesity: results of the BAPO trial. Nutr Metab Cardiovasc Dis. 2021; 31: 3249.
41. Bouter K, Bakker GJ, Levin E et al. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. Clin Transl Gastroenterol. 2018; 9(5): 155.
42. Gill PA, van Zelm MC, Muir JG et al. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment Pharmacol Ther. 2018; 48(1): 15-34.
43. Panufnik P, Więcek M, Szwarc P et al. The effects of sodium butyrate supplementation on the severity of abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes – preliminary data. United European Gastroenterology Journal. 2023; 11(8).
44. Banasiewicz T, Kobiela J, Cwaliński J et al. Rekomendacje w zakresie stosowania prehabilitacji, czyli kompleksowego przygotowania pacjenta do zabiegu operacyjnego. Pol Przegl Chirurg. 2023; 95(4): 62-91.
45. Trone K, Rahman S, Green CH et al. Synbiotics and Surgery: Can Prebioticsand Probiotics Affect Inflammatory Surgical Outcomes? Curr Nutr Rep. 2023; 12(2): 238-46.
46. Motoori M, Tanaka K, Sugimura K et al. Impact of preoperative fecal shortchain fatty acids on postoperative infectious complications in esophageal cancerpatients. BMC Gastroenterol. 2020; 20(1): 74.
47. Hyoju SK, Adriaansens C, Wienholts K et al. Low-fat/high-fibre diet prehabilitationimproves anastomotic healing via the microbiome: an experimental model.Br J Surg. 2020; 107(6): 743-55.
48. Zhang Y, Xu S, Qian Y et al. Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson’s disease by regulating gut microbiota. Front Aging Neurosci. 2023; 15: 1099018.
49. Doifode T, Giridharan VV, Generoso JS et al. The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology. Pharmacol Res. 2021; 164: 105314.
50. Szentirmai É, Millican NS, Massie AR et al. Butyrate, a metabolite of intestinal bacteria, enhances sleep. Sci Rep. 2019; 9(1): 7035.
51. Li Y, Li H, Wang R et al. Protective effect of sodium butyrate on intestinal barrier damage and uric acid reduction in hyperuricemia mice. Biomed Pharmacother. 2023; 161: 114568.
52. Vinarskaya AK, Balaban PM, Roshchin MV et al. Sodium butyrate as a selective cognitive enhancer for weak or impaired memory. Neurobiol Learn Mem. 2021; 180: 107414.
53. Lawrance IC. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol. 2011; 26(1): 36-43.
54. Banasiewicz T, Domagalska D, Borycka-Kiciak K et al. Determination of butyric acid dosage based on clinical and experimental studies – a literature review. Prz Gastroenterol. 2020; 15(2): 119-25.
2. Tsukahara T, Koyama H, Okada M et al. Stimulation of butyrate production by gluconic acid in batch culture of pig cecal digesta and identification of butyrateproducing bacteria. J Nutr. 2002; 132: 222934.
3. Kiani AK, Medori MC, Bonetti G et al. Modern vision of the Mediterranean diet. J Prev Med Hyg. 2022; 63(2 Suppl 3): E36-43.
4. Newsome R, Yang Y, Jobin C. Western diet influences on microbiome and carcinogenesis. Semin Immunol. 2023; 67: 101756.
5. García-Montero C, Fraile-Martínez O, Gómez-Lahoz AM et al. Nutritional Components in Western Diet Versus Mediterranean Diet at the Gut Microbiota-Immune System Interplay. Implications for Health and Disease. Nutrients. 2021; 13(2): 699.
6. Coppola S, Avagliano C, Calignano A et al. The Protective Role of Butyrate against Obesity and Obesity-Related Diseases. Molecules. 2021; 26: 682.
7. Banasiewicz T. Badanie porównujące profil uwalniania się w jelicie aktualnie dostępnych na rynku polskim produktów zawierających maślan sodu. Med Fakt. 2017; 4(37).
8. Chapman MA, Grahn MF, Boyle MA et al. Butyrate oxidation is impaired in the colonic mucosa of sufferers of quiescent ulcerative colitis. Gut. 1994; 35(1): 73-6.
9. Tarnowski W, Borycka-Kiciak K, Kiciak A et al. Efekty leczenia kwasem masłowym w zespole jelita drażliwego – doniesienie wstępne. Gastroenterol Prakt. 2013; 1 : 43-8.
10. Leonel AJ, Alvarez-Leite JI. Butyrate: implications for intestinal function. Curr Opin Clin Nutr Metab Care. 2012; 15(5): 474-9.
11. Załęski A, Banaszkiewicz A, Walkowiak J. Butyric acid in irritable bowel syndrome. Prz Gastroenterol. 2013; 15(2): 204-49.
12. Pozuelo M, Panda S, Santiago A et al. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome. Sci Rep. 2015; 5: 12693.
13. Banasiewicz T, Krokowicz Ł, Stojcev Z et al. Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. Colorectal Dis. 2013; 15(2): 204-9.
14. Lewandowski K, Kaniewska M, Karłowicz K et al. The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome. Prz Gastroenterol. 2022; 17(1): 28-34.
15. Parada Venegas D, De la Fuente MK, Landskron G et al. Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front Immunol. 2019; 10: 277.
16. Deleu S, Machiels K, Raes J et al. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine. 2021; 66: 103293.
17. Facchin S, Vitulo N, Calgaro M et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil. 2020; 32(10): e13914.
18. Pietrzak A, Banasiuk M, Szczepanik M et al. Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial. Nutrients. 2022; 14(16): 3283.
19. Karłowicz K, Lewandowski K, Tulewicz-Marti E et al. P876 Efficacy and safety of microencapsulated butyrate add-on therapy in induction of remission in patients with mild-to-moderate Ulcerative Colitis – results from multi-center, double-blind, randomized, placebo-controlled clinical study. Journal of Crohn’s and Colitis. 2024; 18(1): i1618.
20. Krokowicz L, Stojcev Z, Kaczmarek BF et al. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis – a prospective randomized study. Int J Colorectal Dis. 2014; 29(3): 387-93.
21. Bajka BH, Clarke JM, Topping DL et al. Butyrylated starch increases large bowel butyrate levels and lowers colonic smooth muscle contractility in rats. Nut Res. 2010; 30: 427-34.
22. Hodgkinson K, El Abbar F, Dobranowski P et al. Butyrate’s role in human health and the current progress towards its clinical application to treat gastrointestinal disease. Clin Nutr. 2023; 42(2): 61-75.
23. Tseng CH, Wu CY. The gut microbiome in obesity. J Formos Med Assoc. 2019; 118(Suppl 1): S3-S9.
24. van Deuren T, Blaak EE, Canfora EE. Butyrate to combat obesity and obesity-associated metabolic disorders: Current status and future implications for therapeutic use. Obes Rev. 2022; 23(10): e13498.
25. Zhou D, Chen YW, Zhao ZH et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med. 2018; 50(12): 1-12.
26. Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. Chem Biol Interact. 2016; 254: 124-34.
27. Park M, Kwon J, Shin HJ et al. Butyrate enhances the efficacy of radiotherapy via FOXO3A in colorectal cancer patientderived organoids. Int J Oncol. 2020; 57(6): 1307-18.
28. Encarnação JC, Pires AS, Amaral RA et al. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. J Nutr Biochem. 2018; 56: 183-92.
29. Xi Y, Jing Z, Wei W et al. Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network. BMC Cancer. 2021; 21(1): 127.
30. Pinto A, Fidalgo P, Cravo M et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double- blind, controlled trial. Dis Colon Rectum. 1999; 42(6): 788-95.
31. Harig JM, Soergel KH, Komorowski RA et al. Treatment of diversion colitis with short-chain-fatty acid irrigation. N Engl J Med. 1989; 320(1): 23-8.
32. Mortensen FV, Hessov I, Birke H et al. Microcirculatory and trophic effects of short chain fatty acids in the human rectum after Hartmann’s procedure. Br J Surg. 1991; 78(10): 1208-11.
33. Brown AJ, Goldsworthy SM, Barnes AA et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003; 278(13): 11312-9.
34. Nilsson NE, Kotarsky K, Owman C et al. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem Biophys Res Commun. 2003; 303: 1047-52.
35. Tolhurst G, Heffron H, Lam YS et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2012; 61(2): 364-71.
36. Yadav H, Lee JH, Lloyd J et al. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013; 288(35): 25088-97.
37. Nohr MK, Pedersen MH, Gille A et al. GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology. 2013; 154(10): 3552-64.
38. Khan S, Jena G. Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin. Chem Biol Interact. 2016; 254: 124-34.
39. Roshanravan N, Mahdavi R, Alizadeh E et al. Effect of Butyrate and Inulin Supplementation on Glycemic Status, Lipid Profile and Glucago-Like Peptide 1 Level in Patients with Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. Horm Metab Res. 2017; 49(11): 886-91.
40. Coppola S, Nocerino R, Paparo L et al. Butyrate against paediatric obesity: results of the BAPO trial. Nutr Metab Cardiovasc Dis. 2021; 31: 3249.
41. Bouter K, Bakker GJ, Levin E et al. Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. Clin Transl Gastroenterol. 2018; 9(5): 155.
42. Gill PA, van Zelm MC, Muir JG et al. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. Aliment Pharmacol Ther. 2018; 48(1): 15-34.
43. Panufnik P, Więcek M, Szwarc P et al. The effects of sodium butyrate supplementation on the severity of abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes – preliminary data. United European Gastroenterology Journal. 2023; 11(8).
44. Banasiewicz T, Kobiela J, Cwaliński J et al. Rekomendacje w zakresie stosowania prehabilitacji, czyli kompleksowego przygotowania pacjenta do zabiegu operacyjnego. Pol Przegl Chirurg. 2023; 95(4): 62-91.
45. Trone K, Rahman S, Green CH et al. Synbiotics and Surgery: Can Prebioticsand Probiotics Affect Inflammatory Surgical Outcomes? Curr Nutr Rep. 2023; 12(2): 238-46.
46. Motoori M, Tanaka K, Sugimura K et al. Impact of preoperative fecal shortchain fatty acids on postoperative infectious complications in esophageal cancerpatients. BMC Gastroenterol. 2020; 20(1): 74.
47. Hyoju SK, Adriaansens C, Wienholts K et al. Low-fat/high-fibre diet prehabilitationimproves anastomotic healing via the microbiome: an experimental model.Br J Surg. 2020; 107(6): 743-55.
48. Zhang Y, Xu S, Qian Y et al. Sodium butyrate ameliorates gut dysfunction and motor deficits in a mouse model of Parkinson’s disease by regulating gut microbiota. Front Aging Neurosci. 2023; 15: 1099018.
49. Doifode T, Giridharan VV, Generoso JS et al. The impact of the microbiota-gut-brain axis on Alzheimer’s disease pathophysiology. Pharmacol Res. 2021; 164: 105314.
50. Szentirmai É, Millican NS, Massie AR et al. Butyrate, a metabolite of intestinal bacteria, enhances sleep. Sci Rep. 2019; 9(1): 7035.
51. Li Y, Li H, Wang R et al. Protective effect of sodium butyrate on intestinal barrier damage and uric acid reduction in hyperuricemia mice. Biomed Pharmacother. 2023; 161: 114568.
52. Vinarskaya AK, Balaban PM, Roshchin MV et al. Sodium butyrate as a selective cognitive enhancer for weak or impaired memory. Neurobiol Learn Mem. 2021; 180: 107414.
53. Lawrance IC. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol. 2011; 26(1): 36-43.
54. Banasiewicz T, Domagalska D, Borycka-Kiciak K et al. Determination of butyric acid dosage based on clinical and experimental studies – a literature review. Prz Gastroenterol. 2020; 15(2): 119-25.